Rowbotham 1998.

Methods	Multicentre, randomised, double‐blind, placebo‐controlled, parallel groups, no enrichment, LOCF 4‐week titration to maximum tolerated dose, or 3600 mg then stable dose for 4 weeks (8 weeks in total)
Participants	PHN. Pain > 3 months after healing of rash, PI at randomisation ≥ 40/100 N = 229 Median age 73 years, 48% women Initial average daily pain 6.4/10
Interventions	Gabapentin 3600 mg daily (max), n = 113; (83% had ≥ 2400 mg daily) Placebo, n = 116
Outcomes	PGIC moderate or much improved PGIC CTR moderate and much improved No change in pain SF36 and QoL Adverse events Withdrawals
Notes	Oxford Quality Score: R = 1, DB = 2, W = 1, Total = 3 Parke‐Davies sponsored
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Low risk	"subject‐specific bottles based on randomisation schedule"
Blinding (performance bias and detection bias) All outcomes	Low risk	"identically appearing capsules"
Incomplete outcome data (attrition bias) Efficacy	Unclear risk	LOCF imputation
Size Efficacy	Unclear risk	50‐200 participants per treatment arm (113, 116)